Synta cuts jobs after melanoma trial suspension
This article was originally published in Scrip
Executive Summary
Synta Pharmaceuticals will axe nearly 40% of its staff as it tries to buy time following the suspension of a trial of its lead candidate elesclomol. The reductions will allow Synta to operate on its current reserves for more than two years without approaching the capital markets.